Empowering human-first diagnostic solutions

Bryon leads the architecture of Aranscia’s synergistic team and platform, leveraging his in-depth knowledge of the healthcare industry from nearly 30 years of operating experience.  Bryon’s prior roles with clinical, revenue cycle, and technology companies to included designing medication management solutions, implementing accountable care programs to physician groups, and consulting for molecular diagnostic laboratories and healthcare organizations.

Dave oversees the Aranscia operations infrastructure and has over 35 years of experience leading healthcare IT, operations, and software development organizations. Dave was the co-founder of the MedTek21 precision medication platform (acquired by Aranscia), and has led the development of numerous healthcare IT infrastructure software platforms.  Dave previously served as an infrastructure consultant for a variety of companies, including AmerisourceBergen, and has held executive operations and technology roles with companies such as Russell Stover, Western Auto, and Payless ShoeSource.

Joe leads Aranscia’s product and corporate development initiatives, and brings extensive experience as an operator, investor, and advisor.  Joe was a founding team member and Chief Commercial Officer for the MedTek21 platform, where his responsibilities included the platform’s launch and development of pharmacogenomics partner relationships across multiple verticals. Joe previously held senior investment roles in the venture capital and private equity industries with groups including NXT Capital and Velocity Financial Group, as well as a background in technology investment banking with Harris Williams & Co.

Grattan is a highly accomplished healthcare IT professional with 25+ years of experience in growth, execution, and leadership. Grattan oversees sales operations across the entire Aranscia portfolio and brings with him proven success at Fortune 500 corporations, growth-stage companies, and startup ventures, having served in a variety of roles: business development, strategy, sales, management, and consulting.

Rey has a 30-plus year career as a senior finance leader, developing deep accounting and finance expertise as an auditor, investment banker, consultant, and chief financial officer. Prior to joining Aranscia, Rey served as CFO for Baylor Genetics Laboratories, where he was responsible for the accounting, finance, revenue cycle management, corporate strategy, IT, and legal functions.

Dr. Joel Diamond brings extensive practical clinical and technology implementation experience to Aranscia. He formerly served as CMIO and chairman of the Physician Advisory Board at the University of Pittsburgh Medical Center, St. Margaret Memorial Hospital, where he facilitated 100% adoption of CPOE in a community hospital setting.  He helped develop dbMotion, a solution for health information exchange and population health. Dr. Diamond currently serves as an adjunct associate professor of biomedical informatics at the University of Pittsburgh. He is a diplomat of the American Board of Family Practice and a fellow in the American Academy of Family Physicians while continuing to care for patients at Handelsman Family Practice in Pittsburgh, PA.

Assaf is the founder and chief executive officer of 2bPrecise, leading an international team dedicated to bridging the final mile between the science of genomics and making that data useful at the point of care. An initial inventor and co-founder of dbMotion, Halevy helped develop the leading clinical integration and population health management platforms in the industry today. Assaf was invited to participate in several U.S. government activities and contribute to an HHS privacy committee task force. In 2016, he was part of a small select group of executives invited to the White House by Vice President Joe Biden to discuss the future of interoperability.

Shelly Buchman is a veteran legal professional with over 22 years of legal, human resources, and business compliance experience.  Shelly currently serves as Aranscia’s Chief Compliance Officer and leads the Aranscia global talent organization. Prior to her role wiith Aranscia, Shelly spent more than 15 years in various legal roles in the energy sector.

Houda serves on the Clinical Pharmacogenetics Implementation Consortium (CPIC) Scientific Advisory Board and is an active member of the Pharmacogene Variation Consortium (PharmVar). She is involved with several pharmacogenomics working groups and committees aimed at standardizing pharmacogenomic testing modalities and at facilitating their adoption by the clinical community. Houda has overseen the development of pharmacogenetic product line extensions from inception to delivery and spearheaded the operational efforts for translating scientific requirements into technology solutions.

Kristine has worked in pharmacogenomics since 2000 and was named one of the 25 leading global voices in precision medicine. She is the Founder and President of YouScript, an award-winning clinical decision support tool that has integrated PGx-guided personalized prescribing in the clinical workflow for over a decade. Kristine has 25+ years experience in various C-level, board, customer success and business development roles. She has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing and serves on numerous PGx advisory groups including the STRIPE Steering Committee, the FDA collaborative community for pharmacogenomics, CPIC, and the American Cancer Society Cancer Action Network PGx task force.

Dr. Burns C. Blaxall is the Senior Vice President of Precision Medicine at Aranscia. He previously served as the founding Executive Director of Precision Health at The Christ Hospital Health Network, developing a nationally recognized program for proactive, individualized care, including initiation of a prospective, randomized, controlled trial of comprehensive pharmacogenomics. He has served as principal investigator on dozens of NIH and foundation grants, including most recently $1M for underserved populations. He received his PhD in Pharmacology from the University of Colorado and has held positions at Duke University, the University of Rochester and the University of Cincinnati. Dr. Blaxall holds several patents and has published nearly 100 peer-reviewed manuscripts. He has received numerous honors and awards and holds leadership roles in professional societies and boards for Precision Medicine and therapeutic discovery.